| JaLCDOI | 10.18926/AMO/60799 |
|---|---|
| FullText URL | 74_5_401.pdf |
| Author | Tsukioki, Takahiro| Shien, Tadahiko| Ohtani, Yusuke| Fujihara, Miwa| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| |
| Abstract | Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution. We retrospectively investigated prognosis and factors including sex, reason for discovery, treatment, pathological factors and treatment progress to clarify the risk factors. All patients underwent curative surgical treatment. Pathologically, lymph node metastasis was identified in 25 patients (75%). Thirteen patients (39%) had bilateral cervical metastasis. In addition, 9 (27%) had more than 10 metastatic lymph nodes. The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI). Five patients (15%) had local recurrences and received surgery. There have been no further recurrences or deaths. However, no factors were determined to significantly predict the recurrence of juvenile DTC. Local recurrent disease was treated with surgery and/or RAI until remission, and survival was excellent in juvenile DTC. |
| Keywords | differentiated thyroid carcinoma juvenile children |
| Amo Type | Original Article |
| Published Date | 2020-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume74 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 401 |
| End Page | 406 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33106695 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Tsukioki, Takahiro| Shien, Tadahiko| Doihara, Hiroyoshi| |
| Keywords | Breast cancer metastatic stage IV local therapy locoregional therapy surgery survival |
| Published Date | 2020-08 |
| Publication Title | Translational Cancer Research |
| Volume | volume9 |
| Issue | issue8 |
| Publisher | AME Publishing Co. |
| Start Page | 5102 |
| End Page | 5107 |
| ISSN | 2218-676X |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © Translational Cancer Research. All rights reserved. |
| File Version | publisher |
| DOI | 10.21037/tcr.2020.01.60 |
| Web of Science KeyUT | 000562138400067 |
| Related Url | isVersionOf https://doi.org/10.21037/tcr.2020.01.60 |
| Author | Ochi, Kosuke| Suzawa, Ken| Tomida, Shuta| Shien, Kazuhiko| Takano, Jui| Miyauchi, Shunsaku| Takeda, Tatsuaki| Miura, Akihiro| Araki, Kota| Nakata, Kentaro| Yamamoto, Hiromasa| Okazaki, Mikio| Sugimoto, Seiichiro| Shien, Tadahiko| Yamane, Masaomi| Azuma, Kazuo| Okamoto, Yoshiharu| Toyooka, Shinichi| |
|---|---|
| Keywords | Monensin Epithelial-mesenchymal transition Non-small cell lung cancer Drug repositioning Drug resistance |
| Note | This fulltext is available in Jul. 2021.| |
| Published Date | 2020-08-27 |
| Publication Title | Biochemical and Biophysical Research Communications |
| Volume | volume529 |
| Issue | issue3 |
| Publisher | Academic Press |
| Start Page | 760 |
| End Page | 765 |
| ISSN | 0006-291X |
| NCID | AA00564395 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | Author |
| PubMed ID | 32736704 |
| DOI | 10.1016/j.bbrc.2020.06.077 |
| Web of Science KeyUT | 000555780500037 |
| Related Url | iaVersionOf https://doi.org/10.1016/j.bbrc.2020.06.077 |
| FullText URL | CCP_fulltext.pdf |
|---|---|
| Author | Tsukioki, Takahiro| Shien, Tadahiko| Tanaka, Takehiro| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Toyooka, Shinichi| |
| Keywords | Breast cancer Metformin Preoperative Tils CD8 PD-L1 |
| Published Date | 2020-06-12 |
| Publication Title | Cancer Chemotherapy and Pharmacology |
| Volume | volume86 volume86 |
| Issue | issue1 issue1 |
| Publisher | Springer |
| Start Page | 55 55 |
| End Page | 63 63 |
| ISSN | 0344-5704 |
| NCID | AA00598397 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | ©Author(s) |
| File Version | Publisher |
| PubMed ID | 32533334 |
| DOI | 10.1007/s00280-020-04092-2 |
| Web of Science KeyUT | 000539841500002 |
| Related Url | isVersionOf https://doi.org/10.1007/s00280-020-04092-2 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Shien, Tadahiko| |
| Published Date | 2019-03 |
| Publication Title | Translational Cancer Research |
| Volume | volume8 |
| Issue | issueSuppl. 2 |
| Publisher | AME Publishing |
| Start Page | S118 |
| End Page | S119 |
| ISSN | 2218-676X |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | publisher |
| DOI | 10.21037/tcr.2018.11.19 |
| Related Url | isVersionOf https://doi.org/10.21037/tcr.2018.11.19 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Shien, Tadahiko| Iwata, Hiroji| |
| Keywords | breast cancer adjuvant neoadjuvant |
| Note | This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.| |
| Published Date | 2020-01-28 |
| Publication Title | Japanese Journal of Clinical Oncology |
| Volume | volume50 |
| Issue | issue3 |
| Publisher | Oxford University Press |
| Start Page | 225 |
| End Page | 229 |
| ISSN | 0368-2811 |
| NCID | AA00690866 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | Copyright © 2020 Oxford University Press |
| File Version | author |
| PubMed ID | 32147701 |
| DOI | 10.1093/jjco/hyz213 |
| Web of Science KeyUT | 000536439500001 |
| Related Url | isVersionOf https://doi.org/10.1093/jjco/hyz213 |
| Author | Iwamoto, Takayuki| Fujisawa, Tomomi| Shien, Tadahiko| Araki, Kazuhiro| Sakamaki, Kentaro| Sangai, Takafumi| Kikawa, Yuichiro| Takao, Shintaro| Nishimura, Reiki| Takahashi, Masato| Aihara, Tomohiko| Mukai, Hirofumi| aira, Naruto| |
|---|---|
| Keywords | Metastatic breast cancer Endocrine therapies Estrogen receptor-positive HER2-negative Resistance |
| Note | This fulltext is available in May 2021.| |
| Published Date | 2020-05-11 |
| Publication Title | Breast Cancer |
| Publisher | Springer |
| ISSN | 13406868 |
| NCID | AA1103354X |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | author |
| PubMed ID | 32394413 |
| DOI | 10.1007/s12282-020-01095-y |
| Web of Science KeyUT | 000531780600002 |
| Related Url | isVersionOf https://doi.org/10.1007/s12282-020-01095-y |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Takeda, Tatsuaki| Yamamoto, Hiromasa| Suzawa, Ken| Tomida, Shuta| Miyauchi, Shunsaku| Araki, Kota| Nakata, Kentaro| Miura, Akihiro| Namba, Kei| Shien, Kazuhiko| Soh, Junichi| Shien, Tadahiko| Kitamura, Yoshihisa| Sendo, Toshiaki| Toyooka, Shinichi| |
| Keywords | breast cancer drug resistance lung cancer neratinib YES1 |
| Published Date | 2019-12-19 |
| Publication Title | Cancer Science |
| Volume | volume111 |
| Issue | issue3 |
| Publisher | Wiley |
| Start Page | 849 |
| End Page | 856 |
| ISSN | 1347-9032 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2019 The Authors. |
| File Version | publisher |
| PubMed ID | 31856375 |
| DOI | 10.1111/cas.14289 |
| Web of Science KeyUT | 000507433400001 |
| Related Url | isVersionOf https://doi.org/10.1111/cas.14289 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Suzuki, Yoko| Taniguchi, Kohei| Hatono, Minami| Kajiwara, Yukiko| Abe, Yuko| Kawada, Kengo| Tsukioki, Takahiro| Kochi, Mariko| Nishiyama, Keiko| Iwamoto, Takayuki| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Tabata, Masahiro| Yanai, Hiroyuki| Doihara, Hiroyoshi| |
| Keywords | Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma |
| Published Date | 2020-01-16 |
| Publication Title | Surgical Case Reports |
| Volume | volume6 |
| Issue | issue1 |
| Publisher | SpringerOpen |
| Start Page | 25 |
| ISSN | 2198-7793 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © The Author(s). 2020 |
| File Version | publisher |
| PubMed ID | 31950295 |
| DOI | 10.1186/s40792-020-0790-7 |
| Web of Science KeyUT | 000513920900001 |
| Related Url | isVersionOf https://doi.org/10.1186/s40792-020-0790-7 |
| FullText URL | OL17_2_2177.pdf |
|---|---|
| Author | Miyoshi, Yuichiro| Shien, Tadahiko| Ogiya, Akiko| Ishida, Naoko| Yamazaki, Kieko| Horii, Rie| Horimoto, Yoshiya| Masuda, Norikazu| Yasojima, Hiroyuki| Inao, Touko| Osako, Tomofumi| Takahashi, Masato| Tomioka, Nobumoto| Wanifuchi‑Endo, Yumi| Hosoda, Mitsuchika| Doihara, Hiroyoshi| Yamashita, Hiroko| |
| Keywords | breast cancer estrogen receptor positive human epidermal growth factor receptor type 2 negative prognosis tumor infiltrating lymphocytes |
| Published Date | 2018-12-19 |
| Publication Title | Oncology Letters |
| Volume | volume17 |
| Issue | issue2 |
| Publisher | Spandidos Publications |
| Start Page | 2177 |
| End Page | 2186 |
| ISSN | 1792-1074 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | publisher |
| PubMed ID | 30675282 |
| DOI | 10.3892/ol.2018.9853 |
| Web of Science KeyUT | 000459551800096 |
| Related Url | isVersionOf https://doi.org/10.3892/ol.2018.9853 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Takahashi, Yuko| Iwamoto, Takayuki| Suzuki, Yoko| Kajiwara, Yukiko| Hatono, Minami| Tsukioki, Takahiro| Kawada, Kengo| Kochi, Mariko| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| Toyooka, Shinichi| |
| Keywords | Gene expression Hormone receptor positive Residual tumor burden Targeted therapy Triple negative |
| Published Date | 2020-04 |
| Publication Title | Clinical Breast Cancer |
| Volume | volume20 |
| Issue | issue2 |
| Publisher | Elsevier |
| Start Page | 117 |
| End Page | 124 |
| ISSN | 1526-8209 |
| NCID | AA11694891 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | author |
| PubMed ID | 31570267 |
| DOI | 10.1016/j.clbc.2019.07.001 |
| Web of Science KeyUT | 000529805200021 |
| Related Url | isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001 |
| FullText URL | BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf |
|---|---|
| Author | Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Keywords | BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction |
| Published Date | 2017-03 |
| Publication Title | Breast Cancer |
| Volume | volume24 |
| Issue | issue2 |
| Publisher | Japanese Breast Cancer Society |
| Start Page | 288 |
| End Page | 298 |
| ISSN | 1340-6868 |
| NCID | AA1103354X |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja |
| File Version | author |
| PubMed ID | 27179527 |
| DOI | 10.1007/s12282-016-0703-6 |
| Web of Science KeyUT | 000395524900012 |
| Related Url | isVerionOf https://doi.org/10.1007/s12282-016-0703-6 |
| JaLCDOI | 10.18926/AMO/54607 |
|---|---|
| FullText URL | 70_5_425.pdf |
| Author | Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. |
| Keywords | breast cancer phase I trial docetaxel |
| Amo Type | Clinical Study Protocols |
| Published Date | 2016-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 425 |
| End Page | 427 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777441 |
| Web of Science KeyUT | 000388098700018 |
| JaLCDOI | 10.18926/AMO/54514 |
|---|---|
| FullText URL | 70_4_327.pdf |
| Author | Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi| |
| Abstract | A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8＋ T cells, which produce multiple cytokines. |
| Keywords | metformin CD8＋ T cells cancer immunology |
| Amo Type | Clinical Study Protocols |
| Published Date | 2016-08 |
| Publication Title | Acta Medica Okayama |
| Volume | volume70 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 327 |
| End Page | 330 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27549683 |
| Web of Science KeyUT | 000384748600018 |
| JaLCDOI | 10.18926/AMO/53907 |
|---|---|
| FullText URL | 69_6_333.pdf |
| Author | Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro| |
| Abstract | We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients. |
| Keywords | breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features |
| Amo Type | Original Article |
| Published Date | 2015-12 |
| Publication Title | Acta Medica Okayama |
| Volume | volume69 |
| Issue | issue6 |
| Publisher | Okayama University Medical School |
| Start Page | 333 |
| End Page | 338 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26690243 |
| Web of Science KeyUT | 000368434500002 |
| Author | Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro| |
|---|---|
| Published Date | 2013-12-01 |
| Publication Title | BMC Cancer |
| Volume | volume13 |
| Content Type | Journal Article |
| Author | Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos| |
|---|---|
| Published Date | 2014-01 |
| Publication Title | Breast Cancer Research and Treatment |
| Volume | volume143 |
| Issue | issue2 |
| Content Type | Journal Article |
| Author | Hayashi, Tatsuro| Asano, Hiroaki| Toyooka, Shinichi| Tsukuda, Kazunori| Soh, Junichi| Shien, Tadahiko| Taira, Naruto| Maki, Yuho| Tanaka, Norimitsu| Doihara, Hiroyoshi| Nasu, Yasutomo| Huh, Nam-ho| Miyoshi, Shinichiro| |
|---|---|
| Published Date | 2012-05 |
| Publication Title | Journal of Cancer Research and Clinical Oncology |
| Volume | volume138 |
| Issue | issue5 |
| Content Type | Journal Article |
| Title Alternative | Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer |
|---|---|
| FullText URL | 126_25.pdf |
| Author | Mizoo, Taeko| Shien, Tadahiko| Ito, Maiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay. Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection. Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected. Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery. |
| Keywords | OSNA法（OSNA method） センチネルリンパ節（sentinel lymph node） micrometastases CK-19 |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-04-01 |
| Volume | volume126 |
| Issue | issue1 |
| Start Page | 25 |
| End Page | 30 |
| ISSN | 0030-1558 |
| Related Url | http://www.okayama-u.ac.jp/user/oma/ |
| language | 日本語 |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.25 |
| JaLCDOI | 10.18926/AMO/50409 |
|---|---|
| FullText URL | 67_3_165.pdf |
| Author | Shien, Tadahiko| Kinoshita, Takayuki| Seki, Kunihiko| Yoshida, Miwa| Hojo, Takashi| Shimizu, Chikako| Taira, Naruto| Doihara, Hiroyoshi| Akashi-Tanaka, Sadako| Tsuda, Hitoshi| Fujiwara, Yasuhiro| |
| Abstract | While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to individualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response;pCR) and insensitive patients (clinical no change;cNC and clinical progressinve disease;cPD). In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p＝0.045) and histological grade 3 (p＝0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC. |
| Keywords | breast cancer neoadjuvant chemotherapy predictors |
| Amo Type | Original Article |
| Published Date | 2013-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume67 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 165 |
| End Page | 170 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 23804139 |
| Web of Science KeyUT | Pretreatment Specimen Predicts |
